24/7 Market News Snapshot 26 December, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

December 26, 2024

DENVER, Colo., 26 December, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (HOTH) is experiencing a notable moment as it trades at $0.769, reflecting a decline of approximately 2.29% from the previous session’s closure of $0.787. Today’s trading activity demonstrates increased engagement, with a volume of 8.13 million shares exchanged. Despite this recent downturn, the stock may encounter resistance at $0.81 and support near $0.76, suggesting potential volatility that demands careful observation by investors.

In conjunction with its active trading performance, Hoth Therapeutics has announced a significant development. The company has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA) and Emory University. This collaboration revolves around a groundbreaking technology focusing on the “Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions.” This notable advancement aims to address the critical challenges posed by obesity and its associated health implications, allowing Hoth Therapeutics to enhance its portfolio of transformative therapies.

Robb Knie, Chief Executive Officer of Hoth Therapeutics, expressed enthusiasm about the partnership, noting its potential to bring impactful healthcare solutions to the market. The exclusive rights acquired through this agreement empower the company to develop and commercialize products derived from this innovative patent portfolio, aligning with its mission to provide science-driven healthcare advancements.

To further bolster its capabilities, Hoth Therapeutics plans to implement a comprehensive development strategy to facilitate the transition of this technology from research into commercialization. The company’s efforts also extend to securing provisional patent protection for its lead therapeutic, HT-001, broadening its applicability and reaffirming its commitment to addressing unmet medical needs.

As Hoth Therapeutics pursues these strategic initiatives, it remains dedicated to transforming scientific discoveries into effective therapeutic solutions that improve patient outcomes across various health challenges.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.